Ensuring Good Manufacturing Practices for Cell & Gene Therapies: A 10-Point CQV Checklist

With the boom in demand and production of cell and gene therapies (CGT) over the last decade, biopharma manufacturers are continually adapting to capitalize on market trends and address necessary equipment and facility upgrades.

Manufacturers that can strike the right balance of technology, personnel, and partnerships can overcome the CGT market limitations and growing pains to establish and maintain good manufacturing practices (GMP) and capitalize on the market trajectory.

Download this white paper to explore the current state of the U.S. CGT market and review ten commissioning, qualification, and validation strategies CGT companies can use to ensure GMP compliance.